This is an observational, multicenter, open and prospective study. The primary objective is to evaluate safety of risperidone in patients who are overweight and/or obese. It's expected to enroll 1500 patients with Schizophrenia or Schizoaffective disorder, in which physicians considered the use of risperidone as treatment under clinical practice with a BMI (Body Mass Index) >25; patients have increased their body weight >7% in the last year with the previous treatment even with a BMI< 25; and patients that have shown intolerance to a previous antipsychotic treatment. The study drug is risperidone, 3-6 mg per day, orally, during the study period (6 months). All data collected will be prospective and will include the following: demographic data, psychiatric history and comorbidities, concomitant treatment, body weight, treatment history , other illness related to obesity ( such as diabetes mellitus I & II, hypertension and hypercholesterolemia) and adverse events.

Risperidone, 3-6 mg per day, orally, during the study period (6 months).

Inclusion Criteria:

• Patients with Schizophrenia or Schizoaffective disorder, in which physicians considered the use of risperidone as treatment under clinical practice with a BMI >25
• Patients have increased their body weight >7% in the last year with the previous treatment even with a BMI< 25 - Patients that have shown intolerance to a previous antipsychotic treatment

Exclusion Criteria:

• Pregnant or lactating patients
• Patients with psychiatry pathology other than Schizophrenia or schizoaffective disorder
• Patients with neurology pathology except Parkinsonism induced by neuroleptics
• Patients with other severe concomitant pathology
• Patients treated with Risperidone in the last 30 days